AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14984920 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak CK-MB ratios of >10xULN
Number of subjects: 2384
Study 14984920 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous peak CK-MB ratio after PCI
Number of subjects: 2384
Study 11686810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use Emdogain-gel
Number of subjects: 88
Study 11686810 — intervention group
Group type: COMPARATOR
Intervention: Marketed Emdogain
Number of subjects: 88
Study 9542288 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plethysmography, vibrometry, two point discrimination, and monofilament testing
Number of subjects: 0
Study 9542288 — intervention group
Group type: EXPERIMENTAL
Intervention: Various testing modalities utilized in the shipyard medical department
Number of subjects: 0
Study 8147452 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2
Number of subjects: 0
Study 8147452 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% CO2
Number of subjects: 0
Study 8147452 — intervention group
Group type: COMPARATOR
Intervention: Room-air hyperventilation
Number of subjects: 0
Study 3166942 — intervention group
Group type: EXPERIMENTAL
Intervention: Grenz rays alone (4 Gy administered on six occasions at intervals of 1 week)
Number of subjects: 40
Study 3166942 — intervention group
Group type: COMPARATOR
Intervention: Grenz rays combined with topical corticosteroid (betamethasone dipropionate)
Number of subjects: 40
Study 29803341 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 442
Study 29803341 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 442
Study 28748334 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 and -6 supplementation
Number of subjects: 31
Study 28748334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 25466700 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil 20 or 40 mg p.o. t.i.d. for 6 weeks
Number of subjects: 20
Study 23915324 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health messages delivered via email, fax, SMS (cell phone text messaging)
Number of subjects: 528
Study 23915324 — intervention group
Group type: COMPARATOR
Intervention: Control group (no messages received)
Number of subjects: 528
Study 20886505 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Pulse treatment
Number of subjects: 16
Study 20886505 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Pulse treatment
Number of subjects: 16
Study 17653109 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol taste cues
Number of subjects: 37
Study 17653109 — intervention group
Group type: COMPARATOR
Intervention: Appetitive control
Number of subjects: 37
Study 17042839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandated five-channel physiological monitoring
Number of subjects: 402
Study 17042839 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 402
Study 14639081 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-care symptom management intervention (six home visits by registered nurses)
Number of subjects: 0
Study 14639081 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 10820347 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast irradiation
Number of subjects: 837
Study 10820347 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 837
Study 8840852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (1.0 and 0.5 mg or 1.0 and 1.0 mg)
Number of subjects: 266
Study 8840852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 1531484 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg in fasting state
Number of subjects: 26
Study 1531484 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg in nonfasting state
Number of subjects: 26
Study 6372362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (AMCA)
Number of subjects: 230
Study 31922268 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning approaches (support vector machines, random forest, extremely randomized tree, deep learning methods)
Number of subjects: 0
Study 31922268 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models
Number of subjects: 0
Study 29715303 — intervention group
Group type: EXPERIMENTAL
Intervention: TASSH + HIC
Number of subjects: 757
Study 29715303 — intervention group
Group type: COMPARATOR
Intervention: HIC
Number of subjects: 757
Study 27341450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg) combined with lidocaine
Number of subjects: 60
Study 27341450 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine only
Number of subjects: 60
Study 24836393 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-3641 (1.5 Amb a 1-U)
Number of subjects: 1707
Study 24836393 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-3641 (6 Amb a 1-U)
Number of subjects: 1707
Study 24836393 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-3641 (12 Amb a 1-U)
Number of subjects: 1707
Study 24836393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1707
Study 24836393 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-3641 (all doses)
Number of subjects: 1707
Study 23082208 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and certification of pharmacy workers in STD syndrome management
Number of subjects: 1390
Study 23082208 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated patient evaluations
Number of subjects: 1390
Study 23082208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy worker training
Number of subjects: 1390
Study 23082208 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing education for physicians and midwives
Number of subjects: 1390
Study 23082208 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational support from Prevention Salespersons
Number of subjects: 1390
Study 20227636 — intervention group
Group type: EXPERIMENTAL
Intervention: Optive eyedrops, used at least three times a day for one month
Number of subjects: 47
Study 20227636 — intervention group
Group type: COMPARATOR
Intervention: Hylocomod eyedrops, used at least three times a day for one month
Number of subjects: 47
Study 18729147 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet delivered cognitive behavior therapy combined with five group exposure sessions (ICBT+ exp)
Number of subjects: 38
Study 18729147 — intervention group
Group type: COMPARATOR
Intervention: Internet program alone (ICBT)
Number of subjects: 38
Study 16018754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 70
Study 16018754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 12634652 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (oral regimens with treatment durations of > or =7 days)
Number of subjects: 3969
Study 12634652 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (general)
Number of subjects: 3969
Study 12634652 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (low-risk patients)
Number of subjects: 3969
Study 12634652 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (vaginal regimens)
Number of subjects: 3969
Study 12634652 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment in patients with preterm labor
Number of subjects: 3969
Study 10545551 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive hypercapnia (PHC; PaCO2: 45-55 mm Hg)
Number of subjects: 49
Study 10545551 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (NC; PaCO2: 35-45 mm Hg)
Number of subjects: 49
Study 10545551 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive hypercapnia (PHC)
Number of subjects: 49
Study 10545551 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (NC)
Number of subjects: 49
Study 8768849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD; 120 mg, orally)
Number of subjects: 7
Study 8768849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PD and Pirenzepine (PZP; 100 mg, orally)
Number of subjects: 7
Study 8768849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1992739 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride preoperatively
Number of subjects: 38
Study 1992739 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride postoperatively
Number of subjects: 38
Study 1992739 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears postoperatively
Number of subjects: 38
Study 6637785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of cigarette smoking and lowered blood lipid levels
Number of subjects: 0
Study 6637785 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 6637785 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic blocker prazosin
Number of subjects: 0
Study 30919809 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous tranexamic acid dissolved in 100 mL of saline (TXA group)
Number of subjects: 176
Study 30919809 — intervention group
Group type: COMPARATOR
Intervention: 100 mL of saline solution (placebo group)
Number of subjects: 176
Study 28248799 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education and exercise program
Number of subjects: 41
Study 28248799 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 41
Study 25922614 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 130
Study 25922614 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospital-based mild group stretching and balance exercises)
Number of subjects: 130
Study 23994183 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients (SP)
Number of subjects: 30
Study 23994183 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 30
Study 21673279 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive topiramate treatment (mean treatment duration = 282 days, titrated to a dose of 25 mg/kg/d with subsequent uptitration to a maximum of 60 mg/kg/d)
Number of subjects: 284
Study 21673279 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive topiramate treatment
Number of subjects: 284
Study 17538537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil containing parenteral nutrition (FO: Lipoplus: LCT40%-MCT50%-FO10%)
Number of subjects: 0
Study 17538537 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (STD: Lipofundin medium‐chain triglyceride (MCT): long‐chain triglyceride (LCT)50%-MCT50%)
Number of subjects: 0
Study 17538537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil containing parenteral nutrition (FO)
Number of subjects: 0
Study 16842478 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mixture 25/75 (Mix 25/75)
Number of subjects: 20
Study 16842478 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 20
Study 12850677 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (within 7 days after onset of symptoms)
Number of subjects: 145
Study 12850677 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative treatment followed by delayed laparoscopic cholecystectomy (6 to 8 weeks later)
Number of subjects: 145
Study 12850677 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 145
Study 12850677 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy
Number of subjects: 145
Study 11350436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lithium gamolenate (700 mg daily for 15 days)
Number of subjects: 278
Study 11350436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous lithium gamolenate (0.28 g/kg)
Number of subjects: 278
Study 11350436 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous lithium gamolenate (0.84 g/kg)
Number of subjects: 278
Study 11350436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous lithium gamolenate with haemolysis
Number of subjects: 278
Study 9303285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium infusion during propofol-nitrous oxide anaesthesia
Number of subjects: 20
Study 9303285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium infusion during isoflurane-nitrous oxide anaesthesia
Number of subjects: 20
Study 9303285 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium clearance
Number of subjects: 20
Study 8134777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms/kg single dose
Number of subjects: 44
Study 8134777 — intervention group
Group type: COMPARATOR
Intervention: Benzyl benzoate 10% application
Number of subjects: 44
Study 3560380 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine
Number of subjects: 55
Study 3560380 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine
Number of subjects: 55
Study 3560380 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 55
Study 29858911 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 25
Study 29858911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40 mg)
Number of subjects: 25
Study 26936417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg twice daily) + peginterferon alfa-2b + ribavirin for 12 weeks
Number of subjects: 93
Study 26936417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg twice daily) + peginterferon alfa-2b + ribavirin for 24 weeks
Number of subjects: 93
Study 24304363 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 19
Study 24304363 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 19
Study 23269509 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia with remifentanil (n=18)
Number of subjects: 37
Study 23269509 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia with remifentanil (n=19)
Number of subjects: 37
Study 21056658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar esters proniosomes (SEs) for transdermal delivery of vinpocetine
Number of subjects: 0
Study 21056658 — intervention group
Group type: COMPARATOR
Intervention: Oral tablet of vinpocetine
Number of subjects: 0
Study 21056658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar esters proniosomes (SEs)
Number of subjects: 0
Study 18003811 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluad (with MF59 adjuvant)
Number of subjects: 256
Study 18003811 — intervention group
Group type: COMPARATOR
Intervention: Agrippal (without adjuvant)
Number of subjects: 256
Study 16575382 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PROP)
Number of subjects: 200
Study 16575382 — intervention group
Group type: EXPERIMENTAL
Intervention: MID\PROP\REMI
Number of subjects: 200
Study 14556923 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg per day)
Number of subjects: 713
Study 14556923 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (1 mg per day)
Number of subjects: 713
Study 11071843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic activity group
Number of subjects: 174
Study 11071843 — intervention group
Group type: COMPARATOR
Intervention: Stretching and toning group
Number of subjects: 174
Study 8679345 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with mechanical ventilation
Number of subjects: 26
Study 8679345 — intervention group
Group type: COMPARATOR
Intervention: Conscious, spontaneous breathing
Number of subjects: 26
Study 1580636 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine-deprived amino acid solution (AO-90)
Number of subjects: 0
Study 1580636 — intervention group
Group type: COMPARATOR
Intervention: Conventional amino acid solution (control group)
Number of subjects: 0
Study 3022852 — intervention group
Group type: EXPERIMENTAL
Intervention: C.O.P.A.C. combination (Cyclophosphamide, Vincristine, Cis‐Platinum, Adriamycin and CCNU)
Number of subjects: 0
Study 3022852 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 0
Study 29042033 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐SC1® (Intervention group)
Number of subjects: 96
Study 29042033 — intervention group
Group type: COMPARATOR
Intervention: DVD (Control group)
Number of subjects: 96
Study 29042033 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 3D‐SC1® and DVD training
Number of subjects: 96
Study 24444469 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine screening with remote retinal photography
Number of subjects: 511
Study 24444469 — intervention group
Group type: COMPARATOR
Intervention: Outpatient binocular indirect ophthalmoscope examinations
Number of subjects: 511
Study 22146780 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 10 weeks in addition to best medical care
Number of subjects: 11
Study 22146780 — intervention group
Group type: COMPARATOR
Intervention: Best medical care (control group)
Number of subjects: 11
Study 20659341 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision aid (DA)
Number of subjects: 0
Study 20659341 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18328872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for PTSD
Number of subjects: 131
Study 17198647 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (5 mg/day) at bedtime
Number of subjects: 58
Study 17198647 — intervention group
Group type: COMPARATOR
Intervention: Torasemide (5 mg/day) upon awakening
Number of subjects: 58
Study 14571073 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose UVA1 phototherapy (48 J/cm2), treated 4 times a week for 5 weeks.
Number of subjects: 0
Study 14571073 — intervention group
Group type: COMPARATOR
Intervention: Control skin (not specified how it was treated).
Number of subjects: 0
Study 10910446 — intervention group
Group type: COMPARATOR
Intervention: Conventional (potentially microbiologically contaminated) dialysate (group I)
Number of subjects: 30
Study 10910446 — intervention group
Group type: EXPERIMENTAL
Intervention: Online-produced ultrapure dialysate (group II)
Number of subjects: 30
Study 8923573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (2 x 3 mg/day)
Number of subjects: 56
Study 8923573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8923573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine
Number of subjects: 56
Study 1571080 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar HBS
Number of subjects: 20
Study 1571080 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR4
Number of subjects: 20
Study 4093974 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A children during cognitive challenge
Number of subjects: 87
Study 4093974 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A children under ambiguous performance standards
Number of subjects: 87
Study 4093974 — intervention group
Group type: COMPARATOR
Intervention: Type B children during cognitive challenge
Number of subjects: 87
Study 31433997 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhalation powder (TIP) administered in three different daily doses as continuous or cyclical regimens for 112 days of double-blind treatment.
Number of subjects: 180
Study 31433997 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered in a double-blind manner for 112 days of treatment.
Number of subjects: 180
Study 29085540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 0
Study 29085540 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-protocol analysis
Number of subjects: 0
Study 26040175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard acrylic based resins
Number of subjects: 24
Study 26040175 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone‐based soft liner
Number of subjects: 24
Study 23086134 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (group A)
Number of subjects: 90
Study 23086134 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (group B)
Number of subjects: 90
Study 23086134 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin (group C)
Number of subjects: 90
Study 22228885 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA) infusion
Number of subjects: 623
Study 19370275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 mcg.kg‐1 during induction
Number of subjects: 120
Study 19370275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 mcg.kg‐1 during induction and Propofol 1 mg.kg‐1 at the end of surgery
Number of subjects: 120
Study 19370275 — intervention group
Group type: COMPARATOR
Intervention: Normal saline at the end of surgery (Control)
Number of subjects: 120
Study 16820557 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC group (CABG and injection of 60.10(6)+/‐31.10(6) BMC)
Number of subjects: 20
Study 16820557 — intervention group
Group type: COMPARATOR
Intervention: Control group (CABG only)
Number of subjects: 20
Study 16820557 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC group
Number of subjects: 20
Study 16820557 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 12628557 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone instructions in chest compressions alone
Number of subjects: 20
Study 12628557 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR including mouth-to-mouth ventilation
Number of subjects: 20
Study 11126523 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary total hip arthroplasty (THA)
Number of subjects: 100
Study 11126523 — intervention group
Group type: COMPARATOR
Intervention: Osteosynthesis
Number of subjects: 100
Study 11126523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support (protein- and energy-enriched food)
Number of subjects: 100
Study 11126523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status (measured by serum albumin levels)
Number of subjects: 100
Study 11126523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment
Number of subjects: 100